In vivo dosimetry in brachytherapy: Requirements and future directions for research, development, and clinical practice
Brachytherapy can deliver high doses to the target while sparing healthy tissues due to its steep dose gradient leading to excellent clinical outcome. Treatment accuracy depends on several manual steps making brachytherapy susceptible to operational mistakes. Currently, treatment delivery verificati...
| Published in: | Physics and Imaging in Radiation Oncology |
|---|---|
| Main Authors: | , , , , , , , |
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2020-10-01
|
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2405631620300518 |
| _version_ | 1849314424107565056 |
|---|---|
| author | Gabriel P. Fonseca Jacob G. Johansen Ryan L. Smith Luc Beaulieu Sam Beddar Gustavo Kertzscher Frank Verhaegen Kari Tanderup |
| author_facet | Gabriel P. Fonseca Jacob G. Johansen Ryan L. Smith Luc Beaulieu Sam Beddar Gustavo Kertzscher Frank Verhaegen Kari Tanderup |
| author_sort | Gabriel P. Fonseca |
| collection | DOAJ |
| container_title | Physics and Imaging in Radiation Oncology |
| description | Brachytherapy can deliver high doses to the target while sparing healthy tissues due to its steep dose gradient leading to excellent clinical outcome. Treatment accuracy depends on several manual steps making brachytherapy susceptible to operational mistakes. Currently, treatment delivery verification is not routinely available and has led, in some cases, to systematic errors going unnoticed for years. The brachytherapy community promoted developments in in vivo dosimetry (IVD) through research groups and small companies. Although very few of the systems have been used clinically, it was demonstrated that the likelihood of detecting deviations from the treatment plan increases significantly with time-resolved methods. Time–resolved methods could interrupt a treatment avoiding gross errors which is not possible with time-integrated dosimetry. In addition, lower experimental uncertainties can be achieved by using source-tracking instead of direct dose measurements. However, the detector position in relation to the patient anatomy remains a main source of uncertainty. The next steps towards clinical implementation will require clinical trials and systematic reporting of errors and near-misses. It is of utmost importance for each IVD system that its sensitivity to different types of errors is well understood, so that end-users can select the most suitable method for their needs. This report aims to formulate requirements for the stakeholders (clinics, vendors, and researchers) to facilitate increased clinical use of IVD in brachytherapy. The report focuses on high dose-rate IVD in brachytherapy providing an overview and outlining the need for further development and research. |
| format | Article |
| id | doaj-art-ec86ce32b47d4e9a8d637eaea0f529fa |
| institution | Directory of Open Access Journals |
| issn | 2405-6316 |
| language | English |
| publishDate | 2020-10-01 |
| publisher | Elsevier |
| record_format | Article |
| spelling | doaj-art-ec86ce32b47d4e9a8d637eaea0f529fa2025-09-03T03:19:24ZengElsevierPhysics and Imaging in Radiation Oncology2405-63162020-10-011611110.1016/j.phro.2020.09.002In vivo dosimetry in brachytherapy: Requirements and future directions for research, development, and clinical practiceGabriel P. Fonseca0Jacob G. Johansen1Ryan L. Smith2Luc Beaulieu3Sam Beddar4Gustavo Kertzscher5Frank Verhaegen6Kari Tanderup7Department of Radiation Oncology (Maastro), GROW School for Oncology, Maastricht University Medical Centre+, Maastricht, Doctor Tanslaan 12, 6229 ET Maastricht, the Netherlands; Corresponding author.Department of Oncology, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, DK-8200 Aarhus, DenmarkAlfred Health Radiation Oncology, Alfred Health, 55 Commercial Rd, Melbourne, VIC 3004, AustraliaDepartment of Physics, Engineering Physics & Optics and Cancer Research Center, Université Laval, Quebec City, QC, Canada; Department of Radiation Oncology, Research Center of CHU de Québec, Université Laval, Quebec City, QC, CanadaDepartment of Radiation Physics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Unit 1420, Houston, TX 77030, United StatesDepartment of Oncology, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, DK-8200 Aarhus, DenmarkDepartment of Radiation Oncology (Maastro), GROW School for Oncology, Maastricht University Medical Centre+, Maastricht, Doctor Tanslaan 12, 6229 ET Maastricht, the NetherlandsDepartment of Oncology, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, DK-8200 Aarhus, DenmarkBrachytherapy can deliver high doses to the target while sparing healthy tissues due to its steep dose gradient leading to excellent clinical outcome. Treatment accuracy depends on several manual steps making brachytherapy susceptible to operational mistakes. Currently, treatment delivery verification is not routinely available and has led, in some cases, to systematic errors going unnoticed for years. The brachytherapy community promoted developments in in vivo dosimetry (IVD) through research groups and small companies. Although very few of the systems have been used clinically, it was demonstrated that the likelihood of detecting deviations from the treatment plan increases significantly with time-resolved methods. Time–resolved methods could interrupt a treatment avoiding gross errors which is not possible with time-integrated dosimetry. In addition, lower experimental uncertainties can be achieved by using source-tracking instead of direct dose measurements. However, the detector position in relation to the patient anatomy remains a main source of uncertainty. The next steps towards clinical implementation will require clinical trials and systematic reporting of errors and near-misses. It is of utmost importance for each IVD system that its sensitivity to different types of errors is well understood, so that end-users can select the most suitable method for their needs. This report aims to formulate requirements for the stakeholders (clinics, vendors, and researchers) to facilitate increased clinical use of IVD in brachytherapy. The report focuses on high dose-rate IVD in brachytherapy providing an overview and outlining the need for further development and research.http://www.sciencedirect.com/science/article/pii/S2405631620300518In vivo dosimetryBrachytherapyTreatment verification |
| spellingShingle | Gabriel P. Fonseca Jacob G. Johansen Ryan L. Smith Luc Beaulieu Sam Beddar Gustavo Kertzscher Frank Verhaegen Kari Tanderup In vivo dosimetry in brachytherapy: Requirements and future directions for research, development, and clinical practice In vivo dosimetry Brachytherapy Treatment verification |
| title | In vivo dosimetry in brachytherapy: Requirements and future directions for research, development, and clinical practice |
| title_full | In vivo dosimetry in brachytherapy: Requirements and future directions for research, development, and clinical practice |
| title_fullStr | In vivo dosimetry in brachytherapy: Requirements and future directions for research, development, and clinical practice |
| title_full_unstemmed | In vivo dosimetry in brachytherapy: Requirements and future directions for research, development, and clinical practice |
| title_short | In vivo dosimetry in brachytherapy: Requirements and future directions for research, development, and clinical practice |
| title_sort | in vivo dosimetry in brachytherapy requirements and future directions for research development and clinical practice |
| topic | In vivo dosimetry Brachytherapy Treatment verification |
| url | http://www.sciencedirect.com/science/article/pii/S2405631620300518 |
| work_keys_str_mv | AT gabrielpfonseca invivodosimetryinbrachytherapyrequirementsandfuturedirectionsforresearchdevelopmentandclinicalpractice AT jacobgjohansen invivodosimetryinbrachytherapyrequirementsandfuturedirectionsforresearchdevelopmentandclinicalpractice AT ryanlsmith invivodosimetryinbrachytherapyrequirementsandfuturedirectionsforresearchdevelopmentandclinicalpractice AT lucbeaulieu invivodosimetryinbrachytherapyrequirementsandfuturedirectionsforresearchdevelopmentandclinicalpractice AT sambeddar invivodosimetryinbrachytherapyrequirementsandfuturedirectionsforresearchdevelopmentandclinicalpractice AT gustavokertzscher invivodosimetryinbrachytherapyrequirementsandfuturedirectionsforresearchdevelopmentandclinicalpractice AT frankverhaegen invivodosimetryinbrachytherapyrequirementsandfuturedirectionsforresearchdevelopmentandclinicalpractice AT karitanderup invivodosimetryinbrachytherapyrequirementsandfuturedirectionsforresearchdevelopmentandclinicalpractice |
